Literature DB >> 6947890

Intracranial bleeding during therapy with L-asparaginase in childhood acute lymphocytic leukemia.

C Urban, W D Sager.   

Abstract

Two patients developed clinical features of intracranial bleeding--which were confirmed by computerized axial tomograms--during their induction therapy for acute lymphocytic leukemia. Coagulation studies showed clotting abnormalities including severe hypofibrinogenemia. These findings most probably were related to the effect of L-asparaginase which was part of the treatment protocol. Central nervous system leukemia, intrathecal chemotherapy, cranial irradiation, extreme leukocytosis, or thrombopenia at the time of diagnosis or day of stroke did not appear to be predisposing factors in these cases.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6947890     DOI: 10.1007/bf00443266

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  24 in total

1.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

2.  The association of fatal intracranial hemorrhage and blastic crisis in patients with acute leukemia.

Authors:  R D FRITZ; C E FORKNER; E J FREIREICH; E FREI; L B THOMAS
Journal:  N Engl J Med       Date:  1959-07-09       Impact factor: 91.245

3.  The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia.

Authors:  N K Ramsay; P F Coccia; W Krivit; M E Nesbit; J R Edson
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

4.  Familial thrombosis due to antithrombin 3 deficiency.

Authors:  E Marciniak; C H Farley; P A DeSimone
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

5.  Toxicity of E. coli L-asparaginase in man.

Authors:  H F Oettgen; P A Stephenson; M K Schwartz; R D Leeper; L Tallai; C C Tan; B D Clarkson; R B Golbey; I H Krakoff; D A Karnofsky; M L Murphy; J H Burchenal
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

6.  L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.

Authors:  C M Haskell; G P Canellos; B G Leventhal; P P Carbone; J B Block; A A Serpick; O S Selawry
Journal:  N Engl J Med       Date:  1969-11-06       Impact factor: 91.245

7.  Extreme leukemic leukocytosis (blast crisis) in childhood.

Authors:  J C Dearth; K S Fountain; W A Smithson; E O Burgert; G S Gilchrist
Journal:  Mayo Clin Proc       Date:  1978-04       Impact factor: 7.616

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.

Authors:  J A Ortega; M E Nesbit; M H Donaldson; R E Hittle; J Weiner; M Karon; D Hammond
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

10.  Afibrinogenemia with intracerebral hematoma. Report of a successfully treated case.

Authors:  R Montgomery; S E Natelson
Journal:  Am J Dis Child       Date:  1977-05
View more
  3 in total

1.  Neurosurgical management of L-asparaginase induced haemorrhagic stroke.

Authors:  Elisha Ogbodo; Chandrasekaran Kaliaperumal; Michael O'Sullivan
Journal:  BMJ Case Rep       Date:  2012-03-08

Review 2.  Cancer and stroke: commonly encountered by clinicians, but little evidence to guide clinical approach.

Authors:  Malin Woock; Nicolas Martinez-Majander; David J Seiffge; Henriette Aurora Selvik; Annika Nordanstig; Petra Redfors; Erik Lindgren; Mayte Sanchez van Kammen; Alexandros Rentzos; Jonathan M Coutinho; Karen Doyle; Halvor Naess; Jukka Putaala; Katarina Jood; Turgut Tatlisumak
Journal:  Ther Adv Neurol Disord       Date:  2022-06-28       Impact factor: 6.430

3.  Intracerebral haemorrhage after the neonatal period.

Authors:  J H Livingston; J K Brown
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.